Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jun:57:279-283.
doi: 10.1016/j.jcrc.2020.03.005. Epub 2020 Mar 10.

A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19

Andrea Cortegiani  1 , Giulia Ingoglia  2 , Mariachiara Ippolito  2 , Antonino Giarratano  2 , Sharon Einav  3
Affiliations

A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19

Andrea Cortegiani et al. J Crit Care. 2020 Jun.

Abstract

Purpose: COVID-19 (coronavirus disease 2019) is a public health emergency of international concern. As of this time, there is no known effective pharmaceutical treatment, although it is much needed for patient contracting the severe form of the disease. The aim of this systematic review was to summarize the evidence regarding chloroquine for the treatment of COVID-19.

Methods: PubMed, EMBASE, and three trial Registries were searched for studies on the use of chloroquine in patients with COVID-19.

Results: We included six articles (one narrative letter, one in-vitro study, one editorial, expert consensus paper, two national guideline documents) and 23 ongoing clinical trials in China. Chloroquine seems to be effective in limiting the replication of SARS-CoV-2 (virus causing COVID-19) in vitro.

Conclusions: There is rationale, pre-clinical evidence of effectiveness and evidence of safety from long-time clinical use for other indications to justify clinical research on chloroquine in patients with COVID-19. However, clinical use should either adhere to the Monitored Emergency Use of Unregistered Interventions (MEURI) framework or be ethically approved as a trial as stated by the World Health Organization. Safety data and data from high-quality clinical trials are urgently needed.

Keywords: COVID-19; Chloroquine; Coronavirus; Pneumonia; SARS-CoV-2.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest AC, GI, MI, AG, SE declare to have no competing interests.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Wu Z., McGoogan J.M. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. Jama. 2020 doi: 10.1001/jama.2020.2648. - DOI - PubMed
    1. Savarino A., Boelaert J.R., Cassone A., Majori G., Cauda R. Effects of chloroquine on viral infections: an old drug against today’s diseases? Lancet Infect Dis. 2003;3:722–727. - PMC - PubMed
    1. Colson P., Rolain J.-M., Raoult D. Chloroquine for the 2019 novel coronavirus SARS-CoV-2. Int J Antimicrob Agents. 2020:105923. - PMC - PubMed
    1. https://www.who.int/blueprint/priority-diseases/keyaction/Table_of_thera... Accessed on 2nd March 2020.
    1. Gao J., Tian Z., Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020 doi: 10.5582/bst.2020.01047. - DOI - PubMed

Publication types